S&P Futures
4,139.75 +9.25 (+0.22%) Dow Futures
34,079.00 +84.00 (+0.25%) Nasdaq Futures
12,586.75 +41.50 (+0.33%) Russell 2000 Futures
1,954.60 +4.70 (+0.24%) Crude Oil
78.46 -0.01 (-0.01%) Gold
1,890.80 +0.10 (+0.01%)
Chart Events
Performance Outlook
| Previous Close | 5.29 |
| Open | 5.20 |
| Bid | 5.12 x 1400 |
| Ask | 5.29 x 1100 |
| Day's Range | 5.19 - 5.39 |
| 52 Week Range | 0.97 - 5.39 |
| Volume | |
| Avg. Volume | 106,853 |
| Market Cap | 138.797M |
| Beta (5Y Monthly) | 1.08 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.34 |
| Earnings Date | Mar 13, 2023 - Mar 17, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 1.40 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for IMRA
Related Research
- IMARA Inc.Daily – Vickers Top Buyers & Sellers for 01/03/2023The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.RatingFair ValueEconomic Moatlast monthArgus Research
- American City Business Journals
Struggling blood disorder biotech shuts down via reverse merger
Imara Inc., the blood disorder-focused company that earlier this year cut its staff to just six people, will be no more following a reverse merger with a Colorado biotech.
- Benzinga
Imara Agrees To Merge With Precision Oncology Player, Shares Surge
Enliven Therapeutics Inc and Imara Inc (NASDAQ: IMRA) agreed to merge in an all-stock transaction. The combined company will focus on advancing Enliven's pipeline of precision oncology product candidates. Enliven is advancing two parallel lead product candidates: ELVN-001 for chronic myeloid leukemia. ELVN-002 for HER2 mutant lung cancer and other HER2-driven tumor types. In September, Imara divested tovinontrine (IMR-687) and all other assets related to its PDE9 program to Cardurion Pharmaceuti
- GlobeNewswire
Enliven Therapeutics and Imara Announce Merger Agreement
Merger to create Nasdaq-listed, clinical-stage biopharmaceutical company focused on advancing Enliven’s portfolio of precision oncology programsCombined company is expected to have a cash balance of approximately $300 million at close, which is expected to provide cash runway through multiple clinical milestones and into early 2026Planned concurrent financing of approximately $165 million co-led by new investors Fairmount and Venrock Healthcare Capital Partners, with participation from additiona
